Abstract

Liquid cultures of the basidiomycetous fungus Gloeophyllum striatum were employed to study the biodegradation of pradofloxacin, a new veterinary fluoroquinolone antibiotic carrying a CN group at position C-8. After 16 days of incubation, metabolites were purified by micro-preparative high-performance liquid chromatography. Four metabolites could be identified by co-chromatography with chemically synthesized standards. The chemical structures of three compounds were resolved by 1H-nuclear magnetic resonance spectroscopy plus infrared spectroscopy in one case. All metabolites were confirmed by high resolution mass spectrometry-derived molecular formulae. They comprised compounds in which the carboxyl group or the fluorine atom had been exchanged for a hydroxyl group. Furthermore, replacement of the CN group and the intact amine moiety by a hydroxyl group as well as degradation of the amine substituent were observed. The chemical structure of a catechol-type fluoroquinolone metabolite (F-5) could be fully defined for the first time. The latter initiated a hypothetical degradation sequence providing a unique metabolite, F-13, which consisted of the cyclopropyl-substituted pyridone ring still carrying C-7 and C-8 of pradofloxacin, now linked by a double bond and substituted by a hydroxyl and the CN group, respectively. Most likely, all reactions were hydroxyl radical-driven. Metabolite F-13 proves fungal cleavage of the aromatic fluoroquinolone core for the first time. Hence, two decades after the emergence of the notion of the non-biodegradability of fluoroquinolones, fungal degradation of all key structural elements has been proven.

Highlights

  • Pradofloxacin (PRA), a new fluoroquinolone (FQ) drug, is used to treat bacterial infections in cats and dogs [Litster et al 2007; Mueller and Stephan 2007]

  • The basic metabolic pathway of PRA, a new veterinary FQ antibacterial drug, in the brown rot fungus G. striatum was similar to schemes established for other FQs such as enrofloxacin, ciprofloxacin and moxifloxacin

  • Hydroxylated primary metabolites of PRA, each representing a different class of compounds (Figure 3), were generated by hydroxyl radical-based decarboxylation (F1), defluorination (F-2) and elimination of CN (F-6)

Read more

Summary

Introduction

Pradofloxacin (PRA), a new fluoroquinolone (FQ) drug, is used to treat bacterial infections in cats and dogs [Litster et al 2007; Mueller and Stephan 2007] It shares the core structure of common cyclopropyl-type FQs [Domagala and Hagen 2003] but carries a cyano group at position C-8 and a bi-cyclic amine at C-7, S,S-pyrrolidinopiperidine ([1S,6S]-2,8-diazabicyclo[4.3.0]non-8-yl); the latter is contained in moxifloxacin [Petersen 2006]. Concerning in vitro antibacterial activity, low mutant prevention concentrations of PRA suggest a high potential for preventing the emergence of resistance under therapy [Wetzstein 2005]. Both substituents in combination are essential for its improved efficacy [Wetzstein and Hallenbach 2011]. PRA should be more readily biodegradable and ecologically favorable than conventional FQs

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call